Belite Bio Inc. (BLTE), a clinical-stage drug development company advancing novel therapeutics for degenerative retinal diseases, is expected to report topline data from its DRAGON trial this quarter.DRAGON is a phase 3 study of the company's lead drug candidate, Tinlarebant, in adolescent patients with Stargardt disease type 1.Stargardt disease type 1 (STGD1), an inherited juvenile form of macula...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.